Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab

Follicular lymphoma is the most common indolent non-Hodgkin’s lymphoma, and because of the incurable nature of this disorder, new therapies are constantly needed. The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and manageable toxicities for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopedote, Paolo, Shadman, Mazyar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024536/
https://www.ncbi.nlm.nih.gov/pubmed/36941881
http://dx.doi.org/10.2147/CMAR.S381493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024536/
https://www.ncbi.nlm.nih.gov/pubmed/36941881
http://dx.doi.org/10.2147/CMAR.S381493

Ejemplares similares